Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice
Joint Authors
Jiang, Bijie
Zhong, Ying
Jin, Jing
Liu, Peiyu
Song, Yu
Zhang, Hui
Sheng, Liang
Zhou, Huifang
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-01-03
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Dysregulated glucagon drives hyperfunction in hepatic glucose output, which is the main cause of persistent hyperglycemia in type 2 diabetes.
Berberine (Zhang et al., 2010) has been used as a hypoglycemic agent, yet the mechanism by which BBR inhibits hepatic gluconeogenesis remains incompletely understood.
In this study, we treated diabetic mice with BBR, tested blood glucose levels, and then performed insulin, glucose lactate, and glucagon tolerance tests.
Intracellular cAMP levels in hepatocytes were determined by ELISA, hepatic gluconeogenetic genes were assayed by RT-qPCR, and the phosphorylation of CREB, which is the transcriptional factor controlling the expression of gluconeogenetic genes, was detected by western blot.
BBR reduced blood glucose levels, improved insulin and glucose tolerance, and suppressed lactate- and glucagon-induced hepatic gluconeogenesis in ob/ob and STZ-induced diabetic mice.
Importantly, BBR blunted glucagon-induced glucose production and gluconeogenic gene expression in hepatocytes, presumably through reducing cAMP, which resulted in the phosphorylation of CREB.
By utilizing a cAMP analogue, adenylate cyclase (AC), to activate cAMP synthetase, and an inhibitor of the cAMP degradative enzyme, phosphodiesterase (PDE), we revealed that BBR accelerates intracellular cAMP degradation.
BBR reduces the intracellular cAMP level by activating PDE, thus blocking activation of downstream CREB and eventually downregulating gluconeogenic genes to restrain hepatic glucose production.
American Psychological Association (APA)
Zhong, Ying& Jin, Jing& Liu, Peiyu& Song, Yu& Zhang, Hui& Sheng, Liang…[et al.]. 2020. Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. Oxidative Medicine and Cellular Longevity،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1205079
Modern Language Association (MLA)
Zhong, Ying…[et al.]. Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. Oxidative Medicine and Cellular Longevity No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1205079
American Medical Association (AMA)
Zhong, Ying& Jin, Jing& Liu, Peiyu& Song, Yu& Zhang, Hui& Sheng, Liang…[et al.]. Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. Oxidative Medicine and Cellular Longevity. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1205079
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1205079